open access

Vol 62, No 1 (2011)
Review article
Published online: 2011-03-01
Submitted: 2013-02-15
Get Citation

Denosumab - a new option in the treatment of osteoporosis

Edward Franek
Endokrynologia Polska 2011;62(1):79-83.

open access

Vol 62, No 1 (2011)
Review article
Published online: 2011-03-01
Submitted: 2013-02-15

Abstract

Denosumab is the international name of a human, monoclonal antibody approved for the treatment of osteoporosis. This antibody is associated with RANK ligand (RANKL), inactivating it. In consequence, the formation and survival of osteoclasts are suppressed, leading to their apoptosis. All this results in lower bone resorption, while bone mineral density (BMD) increases. Denosumab also reduces the risk of vertebral and non-vertebral fractures. This agent is similarly effective in various stages of renal function impairment; it does not impair fracture healing processes nor contribute to atherosclerosis progression in patients with high cardiovascular risks. Following an analysis of adverse effects, performed in the FREEDOM study (in which it was demonstrated that the incidence of the majority of adverse effects observed in the course of denosumab use was similar to that in the placebo group), its safety for patients can definitely be confirmed. (Pol J Endocrinol 2011; 62 (1): 79-83)

Abstract

Denosumab is the international name of a human, monoclonal antibody approved for the treatment of osteoporosis. This antibody is associated with RANK ligand (RANKL), inactivating it. In consequence, the formation and survival of osteoclasts are suppressed, leading to their apoptosis. All this results in lower bone resorption, while bone mineral density (BMD) increases. Denosumab also reduces the risk of vertebral and non-vertebral fractures. This agent is similarly effective in various stages of renal function impairment; it does not impair fracture healing processes nor contribute to atherosclerosis progression in patients with high cardiovascular risks. Following an analysis of adverse effects, performed in the FREEDOM study (in which it was demonstrated that the incidence of the majority of adverse effects observed in the course of denosumab use was similar to that in the placebo group), its safety for patients can definitely be confirmed. (Pol J Endocrinol 2011; 62 (1): 79-83)
Get Citation

Keywords

denosumab; RANK; RANKL; fractures

About this article
Title

Denosumab - a new option in the treatment of osteoporosis

Journal

Endokrynologia Polska

Issue

Vol 62, No 1 (2011)

Pages

79-83

Published online

2011-03-01

Bibliographic record

Endokrynologia Polska 2011;62(1):79-83.

Keywords

denosumab
RANK
RANKL
fractures

Authors

Edward Franek

Important: This website uses cookies.tanya dokter More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl